The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
Source : Importé depuis le centre
To collect comparative evidence on patient reported outcomes of Varithena compared to ETA when used to treat the incompetent great saphenous vein (GSV). ETA will include either radiofrequency ablation or endovenous laser ablation according to the site's standard practice. To provide long term (1-year, 2-year, and 3-year) outcomes.
Source : Importé depuis le centre
RECRUTEMENT
Profil des participants
Limites d'âge
minimum : 18 ans
Sexe(s) des participants
ALL
Source : Importé depuis le centre
Condition médicale (spécialité visée)
Domaine de recherche
Donnée non disponible
Critères de sélection
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
Varithena®
Varithena® (polidocanol injectable foam) 1%
Donnée non disponible
Inconnu
FDA-approved ETA systems
FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
Donnée non disponible
Inconnu
Varithena®
État du recrutement
unknown
Varithena® (polidocanol injectable foam) 1%
FDA-approved ETA systems
État du recrutement
unknown
FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
Données à jour depuis :
19 mars 2026
SITES ET CONTACTS
Centre principal
vascular care connecticut
DARIEN, CONNECTICUT, UNITED STATES
Recrutement local
—
FERMÉ
Projet terminé dans ce centre
Aussi disponible à: HOUMA, (LOUISIANA), SOUTH PORTLAND, (MAINE), ENGLEWOOD, (NEW JERSEY), WASHINGTON D.C., (DISTRICT OF COLUMBIA), NEW YORK, (NEW YORK), STONY BROOK, (NEW YORK), BELLEVUE, (WASHINGTON), HOUSTON, (TEXAS)
Dernière modification :
19 mars 2026
Données à jour depuis :
21 mars
Origine des données :
clinicaltrials.gov
* Age ≥ 18
* Primary GSV incompetence, defined as reflux \> 0.5 seconds on Duplex ultrasound in a single limb (Note the contralateral limb can have varicosities or SVI if intervention is not required within 3 months i.e. asymptomatic)
* Failed conservative therapy (compression, diet, exercise, leg elevation)
* CEAP Clinical Condition Classification C2 - C6
* Vein diameter 5-10mm, inclusive
* GSV treatable length \> 10cm
* Superficial venous disease manifest by clinical symptoms (rVCSS ≥ 4)
* Able to comprehend and sign an informed consent document and complete written study questionnaires
* Willing and able to return for scheduled follow-up visits (7-days, 3-months, 6-months, 12-months, 24-months, and 36-months post-procedure)
* Willingness to comply with post-treatment compression protocol
Exclusion Criteria:
* Allergy to polidocanol, xylocaine, or epinephrine
* Deep vein thrombosis or pulmonary embolism within 3 months prior to randomization or hypercoagulable disorder
* Post thrombotic deep vein disease above the calf veins
* Pregnancy or lactating (within 30 days of randomization)
* Symptomatic peripheral arterial disease or ankle-brachial pressure index (ABPI) \< 0.8
* Previous treatment to targeted incompetent GSV or previous superficial thrombophlebitis in targeted GSV
* Previous venous intervention in affected limb in past 3 months
* Local aneurysmal GSV segments
* Inability to walk unaided
* Inability to wear post-procedure compression bandaging and stockings
* Patients with clinically significant reflux of the small saphenous vein (SSV) or anterior accessory saphenous vein (AASV)
* In the clinical judgement of the investigator, patient who will require ipsilateral deep venous intervention within 3 months following randomized treatment
* In the clinical judgement of the investigator, patient who will require contralateral venous intervention (superficial or deep) within 3 months following randomized treatment
* Patient on therapeutic anticoagulants
* Active malignancy
* Life expectancy \< 2 years
* Documented COVID-19 infection currently or within 2 months prior to randomization
* Enrollment in another clinical trial that could confound the endpoint within 3 months prior to screening or within 3 months following enrollment
Source : Importé depuis le centre
Cohortes
Thérapie ou Intervention proposée
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
Varithena®
Varithena® (polidocanol injectable foam) 1%
Donnée non disponible
Inconnu
FDA-approved ETA systems
FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
Donnée non disponible
Inconnu
Varithena®
État du recrutement
unknown
Varithena® (polidocanol injectable foam) 1%
FDA-approved ETA systems
État du recrutement
unknown
FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
Données à jour depuis :
19 mars 2026
Description de l'étude
Description de l'étude
Résumé de l'étude
The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
Source : Importé depuis le centre
To collect comparative evidence on patient reported outcomes of Varithena compared to ETA when used to treat the incompetent great saphenous vein (GSV). ETA will include either radiofrequency ablation or endovenous laser ablation according to the site's standard practice. To provide long term (1-year, 2-year, and 3-year) outcomes.
Source : Importé depuis le centre
Centres participants
Sites
Centres participants
9
centres
CARDIOVASCULAR INSTITUTE OF THE SOUTH
Houma
LOUISIANA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
ENGLEWOOD HOSPITAL AND MEDICAL CENTER
Englewood
NEW JERSEY, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
LAKE WASHINGTON VASCULAR, LLC
Bellevue
WASHINGTON, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
MEDSTAR GEORGETOWN UNIVERSITY HOSPITAL (LOMBARDI COMPREHENSIVE CANCER CENTER)
Washington d.c.
DISTRICT OF COLUMBIA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
NEW YORK PRESBYTERIAN HOSPITAL/COLUMBIA UNIVERSITY MEDICAL CENTER
New york
NEW YORK, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
STONY BROOK UNIVERSITY HOSPITAL/ STONY BROOK CHILDREN'S
Stony brook
NEW YORK, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
UT PHYSICIANS CARDIOTHORACIC AND VASCULAR SURGERY
Houston
TEXAS, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
VASCULAR CARE CONNECTICUT
Darien
CONNECTICUT, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
VEIN HEALTHCARE CENTER
South portland
MAINE, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
Source d'information
Dernière modification :
19 mars 2026
Données à jour depuis :
21 mars
Origine des données :
clinicaltrials.gov